SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001393905-21-000053
Filing Date
2021-02-09
Accepted
2021-02-09 16:57:26
Documents
10
Period of Report
2021-02-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.05: Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT rtsl_8k.htm 8-K 49722
2 MEMBERSHIP INTEREST PURCHASE AGREEMENT DATED NOVEMBER 30, 2020 rtsl_ex21.htm EX-2.1 93006
3 SETTLEMENT AND MUTUAL RELEASE AGREEMENT DATED FEBRUARY 9, 2021 rtsl_ex101.htm EX-10.1 60372
4 EXCLUSIVE LICENSE AGREEMENT DATED FEBRUARY 9, 2021 rtsl_ex102.htm EX-10.2 71861
5 2020 EQUITY INCENTIVE PLAN rtsl_ex103.htm EX-10.3 154345
6 CODE OF ETHICS rtsl_ex141.htm EX-14.1 32184
7 CHARTER OF THE AUDIT COMMITTEE rtsl_ex991.htm EX-99.1 52726
8 CHARTER OF THE COMPENSATION COMMITTEE rtsl_ex992.htm EX-99.2 18932
9 CHARTER OF THE NOMINATING AND CORPORATE GOVERNANCE COMMITTEE rtsl_ex993.htm EX-99.3 18963
10 WHISTLEBLOWER PROTECTION POLICY rtsl_ex994.htm EX-99.4 23769
  Complete submission text file 0001393905-21-000053.txt   577600
Mailing Address 5580 PETERSON LANE SUITE 200 DALLAS TX 75240
Business Address 5580 PETERSON LANE SUITE 200 DALLAS TX 75240 214-236-1363
Rapid Therapeutic Science Laboratories, Inc. (Filer) CIK: 0001575659 (see all company filings)

IRS No.: 462111820 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 000-55018 | Film No.: 21607339
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences